泽布替尼二线治疗套细胞淋巴瘤的临床观察  

Clinical observation of Zebutinib second-line treatment for mantle cell lymphoma

作　　者：邱流进 赖咏婷 詹涛 肖威 曾庆芳 QIU Liujin;LAI Yongting;ZHAN Tao;XIAO Wei;ZENG Qingfang(Internal Medicine Center,Ganzhou Cancer Hospital,Ganzhou 341000,Jiangxi,China;Department of Integrated Traditional Chinese and Western Medicine,Ganzhou Cancer Hospital,Ganzhou 341000,Jiangxi,China)

机构地区：[1]赣州市肿瘤医院内科中心三区,江西赣州341000 [2]赣州市肿瘤医院中西医结合科,江西赣州341000

出　　处：《中国现代医生》2024年第29期69-72,91,共5页China Modern Doctor

基　　金：江西省卫生健康会科技计划(202212563)。

摘　　要：目的探讨泽布替尼二线治疗套细胞淋巴瘤的临床疗效。方法选取2020年10月至2021年12月赣州市肿瘤医院收治的套细胞淋巴瘤患者80例作为研究对象。采用抽签法将患者分为观察组与对照组,每组40例。对照组患者采取套细胞淋巴瘤的一线联合苯达莫司汀治疗,观察组患者在一线治疗基础上联合泽布替尼进行二线治疗,随访时间2年,评估比较两组患者的临床疗效、肿瘤标志物水平、免疫功能、生存周期、治疗安全性。结果观察组患者的客观缓解率、疾病控制率均高于对照组(P<0.05)。治疗后,观察组患者的乳酸脱氢酶、β2微球蛋白、癌胚抗原均低于对照组(P<0.05)。治疗后,观察组患者的免疫功能指标优于对照组(P<0.05)。观察组患者的无进展生存期、总生存期均高于对照组(P<0.05)。两组的不良反应发生率差异无统计学意义(P>0.05)。结论泽布替尼二线治疗套细胞淋巴瘤效果良好,可降低肿瘤标志物水平,改善患者的免疫功能,延长预后生存期,治疗安全性好。Objective To explore the clinical efficacy of second-line treatment with Zebutinib for mantle cell lymphoma.Methods Totally 80 patients with mantle cell lymphoma admitted to Ganzhou Cancer Hospital from October 2020 to December 2021 were divided into observation group and control group by lottery method,40 cases in each group.The control group received first-line treatment combined Bendamustine for mantle cell lymphoma,while the observation group received second-line treatment combined with Zebutinib on the basis of first-line treatment.The patients were followed up for 2 years.The clinical efficacy,tumor marker levels,immune function,survival cycle and treatment safety of two groups were evaluated and compared.Results The objective remission rate and disease control rate of observation group were higher than those of control group(P<0.05).After treatment,the levels of lactate dehydrogenase,β2-microglobulin and carcinoembryonic antigen of observation group were lower than those of control group(P<0.05).After treatment,the immune function indicators of observation group was better than that of control group(P<0.05).The progression free survival and overall survival of observation group were higher than those of control group(P<0.05).Conclusion Zebutinib second-line treatment for mantle cell lymphoma has a good effect,can reduce tumor marker levels,improve patients immune function,prolong patients survival cycle,and has good treatment safety.

关 键 词：套细胞淋巴瘤 二线治疗 泽布替尼 临床疗效 

分 类 号：R733.1[医药卫生—肿瘤]